|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0010583,
umls-concept:C0013216,
umls-concept:C0021747,
umls-concept:C0026764,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0205390,
umls-concept:C0444956,
umls-concept:C0600510,
umls-concept:C1337108,
umls-concept:C1420459,
umls-concept:C1442989,
umls-concept:C1512162,
umls-concept:C1883712
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1999-10-5
|
|
pubmed:abstractText |
Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study suggested that the rates of complete response (CR) and survival were increased with a regimen that alternated IFN with chemotherapy. The current study was designed to evaluate the effect of adding alternating cycles of IFN or early intensification with high dose cyclophosphamide (HiCy) to the VBMCP regimen for the treatment of multiple myeloma patients.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 1999 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
957-68
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10491521-Adult,
pubmed-meshheading:10491521-Aged,
pubmed-meshheading:10491521-Aged, 80 and over,
pubmed-meshheading:10491521-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10491521-Cardiovascular Diseases,
pubmed-meshheading:10491521-Carmustine,
pubmed-meshheading:10491521-Cyclophosphamide,
pubmed-meshheading:10491521-Hematologic Diseases,
pubmed-meshheading:10491521-Humans,
pubmed-meshheading:10491521-Infection,
pubmed-meshheading:10491521-Interferon Type I,
pubmed-meshheading:10491521-Melphalan,
pubmed-meshheading:10491521-Middle Aged,
pubmed-meshheading:10491521-Multiple Myeloma,
pubmed-meshheading:10491521-Prednisone,
pubmed-meshheading:10491521-Recombinant Proteins,
pubmed-meshheading:10491521-Survival Analysis,
pubmed-meshheading:10491521-Vincristine
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
|
|
pubmed:affiliation |
The Virginia Piper Cancer Institute, Minneapolis, Minnesota 55407, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Clinical Trial, Phase III
|
